Hbm Holdings Ltd 2142.HK:Hong Kong Stock Exchange

*Data is delayed | Exchange | HKD
Last | 11:55 AM CTT
1.14quote price arrow up+0.02 (+1.79%)
Volume
230,000
52 week range
1.01 - 2.11
Loading...
  • Open1.12
  • Day High1.17
  • Day Low1.11
  • Prev Close1.12
  • 52 Week High2.11
  • 52 Week High Date04/27/23
  • 52 Week Low1.01
  • 52 Week Low Date04/19/24

Key Stats

  • Market Cap102.25M
  • Shares Out770.24M
  • 10 Day Average Volume1.81M
  • Dividend-
  • Dividend Yield-
  • Beta2.3
  • YTD % Change-41.24

KEY STATS

  • Open1.12
  • Day High1.17
  • Day Low1.11
  • Prev Close1.12
  • 52 Week High2.11
  • 52 Week High Date04/27/23
  • 52 Week Low1.01
  • 52 Week Low Date04/19/24
  • Market Cap102.25M
  • Shares Out770.24M
  • 10 Day Average Volume1.81M
  • Dividend-
  • Dividend Yield-
  • Beta2.3
  • YTD % Change-41.24

RATIOS/PROFITABILITY

  • EPS (TTM)0.25
  • P/E (TTM)4.58
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Hbm Holdings Ltd

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
HBM Holdings Ltd is an investment holding company mainly engaged in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops...
Wang Jingsong M.D., Ph.D.
Executive Chairman, Chief Executive Officer
Yingying Chen
Chief Financial Officer
Hong Amy Que Ph.D.
Chief Technology Officer
Address
Level 54, Hopewell Centre, 183
Queen's Road East, Wan Chai
Hong Kong